Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report
Immune checkpoint inhibitors (ICIs) are extensively utilized in the treatment of oncological patients, and the immune-related adverse reactions they induce merit close monitoring. This report describes a case of a lung cancer patient who, after receiving chemotherapy in combination with the programm...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534179/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590896146677760 |
|---|---|
| author | Ming-xing Wang Ai-xin Liu Qing-ming Sun Wan-hui Dong |
| author_facet | Ming-xing Wang Ai-xin Liu Qing-ming Sun Wan-hui Dong |
| author_sort | Ming-xing Wang |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) are extensively utilized in the treatment of oncological patients, and the immune-related adverse reactions they induce merit close monitoring. This report describes a case of a lung cancer patient who, after receiving chemotherapy in combination with the programmed death-1 (PD-1) inhibitor sintilimab, presented with systemic fatigue, alterations in mental and behavioral patterns, somnolence, and symptoms of diabetes insipidus, leading to a diagnosis of grade 4 immune-related hypophysitis. The patient experienced symptomatic relief following pulse therapy with dexamethasone sodium phosphate injections (30mg every 12 hours), and was subsequently treated with prednisone acetate tablets (30 mg/day), which were gradually reduced to a physiological replacement dose. The treatment with sintilimab was discontinued, and the patient’s symptoms gradually improved, with normalization of urine output. |
| format | Article |
| id | doaj-art-8d514cd71bb1404bade596ffd7342947 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-8d514cd71bb1404bade596ffd73429472025-01-23T06:56:07ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.15341791534179Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case reportMing-xing Wang0Ai-xin Liu1Qing-ming Sun2Wan-hui Dong3Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Chinese Medicine, Lu’an, ChinaDepartment of Orthopedics Department, Lu’an Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Chinese Medicine, Lu’an, ChinaDepartment of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine, Lu’an, ChinaDepartment of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine, Lu’an, ChinaImmune checkpoint inhibitors (ICIs) are extensively utilized in the treatment of oncological patients, and the immune-related adverse reactions they induce merit close monitoring. This report describes a case of a lung cancer patient who, after receiving chemotherapy in combination with the programmed death-1 (PD-1) inhibitor sintilimab, presented with systemic fatigue, alterations in mental and behavioral patterns, somnolence, and symptoms of diabetes insipidus, leading to a diagnosis of grade 4 immune-related hypophysitis. The patient experienced symptomatic relief following pulse therapy with dexamethasone sodium phosphate injections (30mg every 12 hours), and was subsequently treated with prednisone acetate tablets (30 mg/day), which were gradually reduced to a physiological replacement dose. The treatment with sintilimab was discontinued, and the patient’s symptoms gradually improved, with normalization of urine output.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534179/fullsintilimabhypophysitisdiabetes insipidusadverse reactionsimmune checkpoint inhibitors |
| spellingShingle | Ming-xing Wang Ai-xin Liu Qing-ming Sun Wan-hui Dong Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report Frontiers in Immunology sintilimab hypophysitis diabetes insipidus adverse reactions immune checkpoint inhibitors |
| title | Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report |
| title_full | Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report |
| title_fullStr | Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report |
| title_full_unstemmed | Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report |
| title_short | Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report |
| title_sort | sintilimab for the treatment of lung adenocarcinoma induced immune related hypophysitis a case report |
| topic | sintilimab hypophysitis diabetes insipidus adverse reactions immune checkpoint inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534179/full |
| work_keys_str_mv | AT mingxingwang sintilimabforthetreatmentoflungadenocarcinomainducedimmunerelatedhypophysitisacasereport AT aixinliu sintilimabforthetreatmentoflungadenocarcinomainducedimmunerelatedhypophysitisacasereport AT qingmingsun sintilimabforthetreatmentoflungadenocarcinomainducedimmunerelatedhypophysitisacasereport AT wanhuidong sintilimabforthetreatmentoflungadenocarcinomainducedimmunerelatedhypophysitisacasereport |